

## Correction: Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

In this article (Cancer Prev Res 2013;6:1242–50), which was published in the November 2013 issue of *Cancer Prevention Research* (1), some of the values presented in Table 3 were incorrect due to a coding error in the analysis. The corrected Table 3 and the corresponding Results section with the correct values are below.

**Table 3.** HPV16 and HPV18 antibody stability between months 24, 36, and 48 by number of doses

	1-dose	2-doses <sub>(0/1)</sub>	2-doses <sub>(0/6)</sub>	3-doses	P-value
24–48 months <i>n</i> (%)					
HPV16 <sup>a</sup>					
Stable <sup>c</sup>	68 (87.18)	128 (91.43)	43 (82.69)	106 (88.33)	0.30
Decrease <sup>c</sup>	10 (12.82)	12 (8.57)	9 (17.31)	14 (11.67)	
HPV18 <sup>b</sup>					
Stable	71 (91.03)	128 (91.42)	43 (82.69)	103 (85.83)	0.24
Decrease	7 (8.97)	12 (8.57)	9 (17.31)	17 (14.17)	
36–48 months <i>n</i> (%)					
HPV16					
Stable decrease	74 (94.87)	136 (97.14)	51 (98.08)	117 (97.50)	0.69
	4 (5.13)	4 (2.86)	1 (1.92)	3 (2.50)	
HPV18					
Stable	72 (92.31)	134 (95.71)	51 (98.08)	118 (98.33)	0.15
Decrease	6 (7.69)	6 (4.29)	1 (1.92)	2 (1.67)	

<sup>a</sup>HPV16 Spearman's rank correlation coefficient at 24- and 48-month visits was 0.88 ( $P < 0.0001$ ).

<sup>b</sup>HPV18 Spearman's rank correlation coefficient at 24- and 48-month visits was 0.90 ( $P < 0.0001$ ).

<sup>c</sup>Stable antibodies defined as levels that did not decline by 2-fold or more; a decrease in antibodies as those that declined 2-fold or more.

### Results

HPV16 and HPV18 antibody durability between 24 to 48 and 36 to 48 months is shown in Table 3. By our definition of less than a 2-fold change, stability between 24 to 48 and 36 to 48 months was high in all dose groups (stability<sub>24–48 months</sub> in the one dose group: HPV16 = 87%; HPV18 = 91%; stability<sub>36–48 months</sub> in the one dose group: HPV16 = 95%; HPV18 = 92%; all  $P$  values  $> 0.05$  compared with the other dose groups) and only a small proportion of women had a decline in antibody levels observed between 24 to 48 and 36 to 48 months regardless of number of doses.

In addition, the maximum values for HPV16, 3-dose, 90th percentiles were mistakenly presented in Table 1. The correct 90th percentiles are (in the order they appear in the table) below.

Enrollment: 47.32

1: 2,349.73

6: 2,409.74

12: 6,683.96

24: 2,978.55

36: 2,573.65

48: 1,808.36

Finally, in the footnote for Table 4, the cutoff for HPV16 neutralization was incorrect. The correct cutoff for HPV16 neutralization is 25.1.

The authors regret the errors.

**Reference**

1. Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. *Cancer Prev Res* 2013;6:1242–50.

---

Published online January 7, 2016.

doi: 10.1158/1940-6207.CAPR-15-0373

©2016 American Association for Cancer Research.

# Cancer Prevention Research

## Correction: Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

*Cancer Prev Res* 2016;9:116-117.

**Updated version** Access the most recent version of this article at:  
<http://cancerpreventionresearch.aacrjournals.org/content/9/1/116>

**Cited articles** This article cites 1 articles, 1 of which you can access for free at:  
<http://cancerpreventionresearch.aacrjournals.org/content/9/1/116.full#ref-list-1>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://cancerpreventionresearch.aacrjournals.org/content/9/1/116>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.